SEARCH

SEARCH BY CITATION

References

  • 1
    Kishimoto I, Tokudome T, Nakao K & Kangawa K (2011) The cardiovascular significance of the natriuretic peptide system. FEBS J, in press.
  • 2
    Misono KS, Philo JS, Arakawa T, Ogata CM, Qiu Y, Ogawa H & Young HS (2011) Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase. FEBS J 278, 18181829.
  • 3
    Pandey K (2011) Functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigms. FEBS J 278, 17921807.
  • 4
    Buckley MG, Sethi D, Markandu ND, Sagnella GA, Singer DR & MacGregor GA (1992) Plasma concentration and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci (Lond) 83, 437444.
  • 5
    Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87, 14021412.
  • 6
    Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ & Reeder GS (1986) Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231, 11451147.
  • 7
    Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M & Imura H (1990) Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 323, 757758.
  • 8
    Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S & Espiner EA (1993) Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 76, 832838.
  • 9
    John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG & Smithies O (1995) Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension [published erratum appears in Science 1995 Mar 24;267(5205):1753]. Science 267, 679681.
  • 10
    Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M et al. (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97, 42394244.
  • 11
    Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y et al. (2001) Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 98, 40164021.
  • 12
    Potter LR (2011) Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 130, 7182.
  • 13
    Potter LR, Abbey-Hosch S & Dickey DM (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27, 4772.
  • 14
    Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI et al. (2004) Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 75, 2734.
  • 15
    Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA & Garbers DL (2004) Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci USA 101, 1730017305.
  • 16
    Tsuji T & Kunieda T (2005) A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem 280, 1428814292.
  • 17
    Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M & Smithies O (1999) The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 96, 74037408.
  • 18
    Jaubert J, Jaubert F, Martin N, Washburn LL, Lee BK, Eicher EM & Guenet JL (1999) Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci USA 96, 1027810283.
  • 19
    Gerbes AL & Vollmar AM (1990) Degradation and clearance of atrial natriuretic factors (ANF). Life Sci 47, 11731180.
  • 20
    Ruskoaho H (1992) Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 44, 479602.
  • 21
    Nakao K, Sugawara A, Morii N, Sakamoto M, Yamada T, Itoh H, Shiono S, Saito Y, Nishimura K, Ban T et al. (1986) The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects. Eur J Clin Pharmacol 31, 101103.
  • 22
    Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA & Livesey JH (1986) Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38, 18271833.
  • 23
    Crozier IG, Nicholls MG, Ikram H, Espiner EA, Yandle TG & Jans S (1986) Atrial natriuretic peptide in humans. Production and clearance by various tissues. Hypertension 8, II1115.
  • 24
    Schutten HJ, Henriksen JH & Warberg J (1987) Organ extraction of atrial natriuretic peptide (ANP) in man. Significance of sampling site. Clin Physiol 7, 125132.
  • 25
    Hollister AS, Rodeheffer RJ, White FJ, Potts JR, Imada T & Inagami T (1989) Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J Clin Invest 83, 623628.
  • 26
    Bates ER, McGillem MJ, Mancini GB & Grekin RJ (1989) Pulmonary extraction of immunoreactive atrial natriuretic factor in dogs. Am J Cardiol 63, 372373.
  • 27
    Holmes SJ, Espiner EA, Richards AM, Yandle TG & Frampton C (1993) Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 76, 9196.
  • 28
    Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H & Nicholls MG (1993) Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 69, 414417.
  • 29
    Hunt PJ, Richards AM, Espiner EA, Nicholls MG & Yandle TG (1994) Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 78, 14281435.
  • 30
    Charles CJ, Espiner EA, Richards AM, Nicholls MG & Yandle TG (1995) Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. Am J Physiol 268, R201R207.
  • 31
    Brandt RR, Heublein DM, Aarhus LL, Lewicki JA & Burnett JC Jr (1995) Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. Am J Physiol 269, H326H331.
  • 32
    Palmer SC, Prickett TC, Espiner EA, Yandle TG & Richards AM (2009) Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 54, 612618.
  • 33
    Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA & Lewicki JA (1987) Physiological role of silent receptors of atrial natriuretic factor. Science 238, 675678.
  • 34
    Almeida FA, Suzuki M, Scarborough RM, Lewicki JA & Maack T (1989) Clearance function of type C receptors of atrial natriuretic factor in rats. Am J Physiol 256, R469R475.
  • 35
    Chiu PJ, Tetzloff G, Romano MT, Foster CJ & Sybertz EJ (1991) Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol 260, R208R216.
  • 36
    Nussenzveig DR, Lewicki JA & Maack T (1990) Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem 265, 2095220958.
  • 37
    Rathinavelu A & Isom GE (1991) Differential internalization and processing of atrial-natriuretic-factor B and C receptor in PC12 cells. Biochem J 276, 493497.
  • 38
    Cohen D, Koh GY, Nikonova LN, Porter JG & Maack T (1996) Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 271, 98639869.
  • 39
    Koh GY, Nussenzveig DR, Okolicany J, Price DA & Maack T (1992) Dynamics of atrial natriuretic factor–guanylate cyclase receptors and receptor–ligand complexes in cultured glomerular mesangial and renomedullary interstitial cells. J Biol Chem 267, 1198711994.
  • 40
    Hori R, Inui K, Saito H, Matsukawa Y, Okumura K, Nakao K, Morii N & Imura H (1985) Specific receptors for atrial natriuretic polypeptide on basolateral membranes isolated from rat renal cortex. Biochem Biophys Res Commun 129, 773779.
  • 41
    Olins GM, Spear KL, Siegel NR, Reinhard EJ & Zurcher-Neely HA (1987) Atrial peptide inactivation by rabbit-kidney brush-border membranes. Eur J Biochem 170, 431434.
  • 42
    Koehn JA, Norman JA, Jones BN, LeSueur L, Sakane Y & Ghai RD (1987) Degradation of atrial natriuretic factor by kidney cortex membranes. Isolation and characterization of the primary proteolytic product. J Biol Chem 262, 1162311627.
  • 43
    Olins GM, Spear KL, Siegel NR & Zurcher-Neely HA (1987) Inactivation of atrial natriuretic factor by the renal brush border. Biochim Biophys Acta 901, 97100.
  • 44
    Malito E, Hulse RE & Tang WJ (2008) Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci 65, 25742585.
  • 45
    Kerr MA & Kenny AJ (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137, 477488.
  • 46
    Malfroy B, Swerts JP, Guyon A, Roques BP & Schwartz JC (1978) High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature 276, 523526.
  • 47
    Stephenson SL & Kenny AJ (1987) The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 243, 183187.
  • 48
    Sonnenberg JL, Sakane Y, Jeng AY, Koehn JA, Ansell JA, Wennogle LP & Ghai RD (1988) Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 9, 173180.
  • 49
    Kenny AJ, Bourne A & Ingram J (1993) Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 291(Pt 1), 8388.
  • 50
    Vanneste Y, Michel A, Dimaline R, Najdovski T & Deschodt-Lanckman M (1988) Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem J 254, 531537.
  • 51
    Dickey DM, Yoder AR & Potter LR (2009) A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 284, 1919619202.
  • 52
    Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, Ballew JD, de Andrade M, Burnett JC Jr & Olson TM (2008) Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 359, 158165.
  • 53
    Watanabe Y, Nakajima K, Shimamori Y & Fujimoto Y (1997) Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem Mol Med 61, 4751.
  • 54
    Potter LR, Yoder AR, Flora DR, Antos LK & Dickey DM (2009) Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191, 341366.
  • 55
    Norman JA, Little D, Bolgar M & Di Donato G (1991) Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 175, 2230.
  • 56
    Abassi ZA, Golomb E, Agbaria R, Roller PP, Tate J & Keiser HR (1994) Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11. Br J Pharmacol 113, 204208.
  • 57
    Kishimoto I, Hamra FK & Garbers DL (2001) Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing. Can J Physiol Pharmacol 79, 715722.
  • 58
    Dickey DM & Potter LR (2010) Human B-type natriuretic peptide is not degraded by meprin A. Biochem Pharmacol 80, 10071011.
  • 59
    Brandt RR, Mattingly MT, Clavell AL, Barclay PL & Burnett JC Jr (1997) Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension 30, 184190.
  • 60
    Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Protter A & Kosoglou T (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 271, R373R380.
  • 61
    Margulies KB, Barclay PL & Burnett JC Jr (1995) The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 91, 20362042.
  • 62
    Wegner M, Stasch JP, Hirth-Dietrich C, Dressel J, Voges KP & Kazda S (1995) Interaction of a neutral endopeptidase inhibitor with an ANP-C receptor ligand in anesthetized dogs. Clin Exp Hypertens 17, 861876.
  • 63
    Lu B, Gerard NP, Kolakowski LF Jr, Bozza M, Zurakowski D, Finco O, Carroll MC & Gerard C (1995) Neutral endopeptidase modulation of septic shock. J Exp Med 181, 22712275.
  • 64
    Duckworth WC, Bennett RG & Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19, 608624.
  • 65
    Johnson GR, Arik L & Foster CJ (1989) Metabolism of 125I-atrial natriuretic factor by vascular smooth muscle cells. Evidence for a peptidase that specifically removes the COOH-terminal tripeptide. J Biol Chem 264, 1163711642.
  • 66
    Johnson GR & Foster CJ (1990) Partial characterization of a metalloendopeptidase activity produced by cultured endothelial cells that removes the COOH-terminal tripeptide from 125I-atrial natriuretic factor. Biochem Biophys Res Commun 167, 110116.
  • 67
    Muller D, Baumeister H, Buck F & Richter D (1991) Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. Eur J Biochem 202, 285292.
  • 68
    Muller D, Schulze C, Baumeister H, Buck F & Richter D (1992) Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry 31, 1113811143.
  • 69
    Ralat LA, Guo Q, Ren M, Funke T, Dickey DM, Potter LR & Tang WJ (2011) Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem 286, 46704679.
  • 70
    Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ & Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100, 41624167.
  • 71
    Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, Schultheiss HP, Siems WE & Walther T (2007) Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 101, 875882.
  • 72
    Boerrigter G, Costello-Boerrigter LC, Harty GJ, Huntley BK, Cataliotti A, Lapp H & Burnett JC Jr (2009) B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am J Physiol Regul Integr Comp Physiol 296, R1744R1750.
  • 73
    Koepke JP, Tyler LD, Trapani AJ, Bovy PR, Spear KL, Olins GM & Blaine EH (1989) Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J Pharmacol Exp Ther 249, 172176.
  • 74
    Kukkonen P, Vuolteenaho O & Ruskoaho H (1992) Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Endocrinology 130, 755765.
  • 75
    Okolicany J, McEnroe GA, Koh GY, Lewicki JA & Maack T (1992) Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am J Physiol 263, F546F553.
  • 76
    Hashimoto Y, Nakao K, Hama N, Imura H, Mori S, Yamaguchi M, Yasuhara M & Hori R (1994) Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm Res 11, 6064.
  • 77
    Smith MW, Espiner EA, Yandle TG, Charles CJ & Richards AM (2000) Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 167, 239246.
  • 78
    Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD & Burnett JC Jr (2009) Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 49, 668673.
  • 79
    Lisy O, Huntley BK, McCormick DJ, Kurlansky PA & Burnett JC Jr (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52, 6068.